financetom
Business
financetom
/
Business
/
Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On?
Jul 9, 2025 8:52 AM

Shares of Evoke Pharma Inc ( EVOK ) are trading sharply higher Wednesday morning after the specialty pharmaceutical company announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering its lead product, GIMOTI.

What To Know: The nasal spray is a treatment for adults with moderate to severe symptoms of diabetic gastroparesis. The new patent, which is expected to expire in December 2036, will extend the market exclusivity for GIMOTI®, a non-oral formulation of metoclopramide.

Evoke Pharma ( EVOK ) plans to list the patent in the FDA’s Orange Book, a key move in protecting the drug from generic competition. This news sent the company’s stock price into overdrive, with shares trading significantly higher in Wednesday’s session.

“This new patent allowance adds meaningful value to the GIMOTI® franchise by reinforcing protection around how and in whom the therapy is used,” said Matt D’Onofrio, CEO of Evoke Pharma ( EVOK ).

The company stated this patent strengthens GIMOTI’s position as a critical treatment option for a patient population that often struggles with the effectiveness of traditional pills.

Price Action: According to data from Benzinga Pro, EVOK shares are trading higher by 171.6% to $7.29 Wednesday morning. The stock has a 52-week high of $12.32 and a 52-week low of $1.94.

Read Also: Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036

How To Buy EVOK Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Evoke Pharma’s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Asset manager Guggenheim plans Saudi presence as part of Gulf investment push
Asset manager Guggenheim plans Saudi presence as part of Gulf investment push
Mar 10, 2026
ABU DHABI, Dec 7 (Reuters) - U.S.-based Guggenheim Investments, with assets of about $357 billion, is actively considering an office in Saudi Arabia and wants to capitalise on investment opportunities in infrastructure and transportation as part of its expansion in the Gulf region. The firm has an office in Dubai, the region's top financial and trade hub, and is in...
India issues directive to all airlines mandating adherence to prescribed fare caps
India issues directive to all airlines mandating adherence to prescribed fare caps
Mar 10, 2026
Dec 6 (Reuters) - India's Ministry of Civil Aviation said on Saturday a directive has been issued to all airlines mandating strict adherence to all fare caps that have been prescribed to protect passengers from any form of opportunistic pricing. The price caps will remain in force until India's flight situation fully stabilises, the ministry said in a statement. Air...
UBS may cut further 10,000 jobs by 2027, SonntagsBlick reports
UBS may cut further 10,000 jobs by 2027, SonntagsBlick reports
Mar 10, 2026
VIENNA, Dec 7 (Reuters) - UBS may cut an additional 10,000 jobs by 2027, Swiss paper SonntagsBlick reported on Sunday, not citing where it obtained the information. UBS was not immediately available for comment. ...
Biocon fully integrates Biocon Biologics in $5.5 billion deal
Biocon fully integrates Biocon Biologics in $5.5 billion deal
Mar 10, 2026
* Biocon to acquire stakes via share swaps with Serum Institute, Tata Capital, Activ Pine * Shreehas Tambe to lead combined entity as CEO, managing director * Biocon reviewed IPO, merger options before choosing integration (Adds details in paragraph 5, bullet points, byline, dateline) By Rishabh Jaiswal and Rishika Sadam BENGALURU, Dec 6 (Reuters) - Indian biopharmaceutical company Biocon said...
Copyright 2023-2026 - www.financetom.com All Rights Reserved